Quote Request
DNA Vaccine Development for Pancreatic Cancer
Continuous developments in immuno-oncology have opened an unprecedented path for the emergence of vaccine strategies. Among them, therapeutic DNA cancer vaccines are simple, stable, and safe, and are considered an attractive immunotherapeutic approach to activate the immune system against cancer. Alfa Cytology is a leading custom service provider in PC vaccine research and development. We are committed to providing the best service in DNA vaccine development for PC and guaranteeing the best results for our customers worldwide.
Overview of DNA Cancer Vaccine
DNA-mediated immunizations began in the 1990s, initially for the treatment of influenza. Since then, DNA vaccines have been developed to treat a variety of diseases, including multiple cancers. DNA vaccines are based on bacterial plasmids encoding antigens and ultimately immunostimulatory molecules. Through different delivery strategies (including physical and chemical methods), DNA is transported into the nucleus overcoming extracellular and intracellular barriers. Once in the nucleus, the antigen encoded by the DNA vaccine needs to be expressed and presented on major histocompatibility molecules (MHC) to activate T cells. In addition to the intrinsic components of plasmid DNA that activate the innate immune response, the antigens encoded by DNA vaccines can also be presented via MHC class I and II, thereby activating CD4+ and CD8+ T-cells and indirectly activating humoral immunity.
Fig. 1 Innate and adaptive immune activation induced by DNA vaccines. (Lopes, Alessandra et al., 2021)
Our Services
During DNA vaccine development, we focus on the selection and optimization of optimal antigens to be inserted into plasmid DNA. This is an important step in DNA vaccine development, involving issues such as antigen loss, modification, and tolerance that can increase the immunogenicity of a DNA vaccine and thus trigger a broad immune response. In addition, based on our in-depth understanding of the tumor immunological profile of PC, we help our clients to achieve precise and feasible development applications of PC DNA vaccines.
Antigen Selection
DNA Vaccine Design and Construction
In Vitro and In Vivo Evaluation
Identification of Target Tumor Antigens:
Researchers first need to identify antigens that are specifically expressed on tumor cells, such as mutated proteins or overexpressed proteins.
Gene Sequence Analysis of Antigens:
Determine the gene sequences of these antigens and select the portions most likely to elicit a strong immune response.
Insertion of Antigen Genes:
Insert the DNA sequences encoding the target antigens into a plasmid, a circular DNA fragment used to carry and deliver the genes.
Design to Enhance Immune Response:
The plasmid typically includes elements like enhancers and promoters (such as cytokine genes) to increase antigen expression and immunogenicity.
In Vitro Testing:
Test the expression and function of the DNA vaccine using cell lines in the laboratory to ensure that the antigens in the plasmid are successfully expressed in host cells.
Animal Model Testing:
Test the DNA vaccine's safety, immunogenicity, and anti-tumor effects in mouse or other animal models.
Why Choose Us?
Tailored Solutions
Advanced Technology
Professional Expertise
Collaborative Approach
To provide DNA vaccines that enhance vaccine-induced immune response and treatment efficacy, we focus on three major directions, including the rational selection of coding antigens, optimization of suitable antigens for insertion into plasmid DNA, and provision of comprehensive and reliable preclinical validation studies. If you are interested in learning more about our Pancreatic Cancer vaccine development services, would like to learn more about our services and opportunities to participate in market research, or are interested in a potential partnership or collaboration, please don't hesitate to contact us.
References
- Lopes, Alessandra, Gaëlle Vandermeulen, and Véronique Préat. "Cancer DNA vaccines: current preclinical and clinical developments and future perspectives." Journal of Experimental & Clinical Cancer Research 38.1 (2019): 1-24.
- Cappello, Paola, et al. "Next generation immunotherapy for pancreatic cancer: DNA vaccination is seeking new combo partners." Cancers 10.2 (2018): 51.
